PTC Therapeutics Inc (NASDAQ:PTCT) — Market Cap & Net Worth
Market Cap & Net Worth: PTC Therapeutics Inc (PTCT)
PTC Therapeutics Inc (NASDAQ:PTCT) has a market capitalization of $6.11 Billion ($6.11 Billion) as of June 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #3170 globally and #1115 in its home market, demonstrating a 6.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PTC Therapeutics Inc's stock price $75.14 by its total outstanding shares 82949338 (82.95 Million). Review PTC Therapeutics Inc (PTCT) total liabilities to assess the company's total debt and financial obligations.
PTC Therapeutics Inc Market Cap History: 2015 to 2026
PTC Therapeutics Inc's market capitalization history from 2015 to 2026. Data shows growth from $2.69 Billion to $6.23 Billion (9.14% CAGR).
Index Memberships
PTC Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.44 Trillion | 0.25% | #69 of 976 |
|
NASDAQ Composite
IXIC
|
$40.95 Trillion | 0.01% | #345 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.36% | #45 of 263 |
Weight: PTC Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
PTC Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PTC Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.64x
PTC Therapeutics Inc's market cap is 3.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.23x
PTC Therapeutics Inc's market cap is 9.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $904.98 Million | $82.70 Million | -$142.11 Million | 10.94x | N/A |
| 2017 | $1.38 Billion | $194.39 Million | -$79.00 Million | 7.12x | N/A |
| 2018 | $2.85 Billion | $264.73 Million | -$128.08 Million | 10.75x | N/A |
| 2019 | $3.98 Billion | $306.98 Million | -$251.58 Million | 12.98x | N/A |
| 2020 | $5.06 Billion | $380.77 Million | -$438.16 Million | 13.30x | N/A |
| 2021 | $3.30 Billion | $538.59 Million | -$523.90 Million | 6.13x | N/A |
| 2022 | $3.17 Billion | $698.80 Million | -$559.02 Million | 4.53x | N/A |
| 2023 | $2.29 Billion | $937.82 Million | -$626.60 Million | 2.44x | N/A |
| 2024 | $3.74 Billion | $806.78 Million | -$363.30 Million | 4.64x | N/A |
| 2025 | $6.30 Billion | $1.73 Billion | $682.64 Million | 3.64x | 9.23x |
Competitor Companies of PTCT by Market Capitalization
Companies near PTC Therapeutics Inc in the global market cap rankings as of June 15, 2026.
Key companies related to PTC Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #438 globally with a market cap of $63.06 Billion USD.
- UCB SA (BR:UCB): Ranked #544 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #563 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $444.93 |
| #438 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $63.06 Billion | $612.14 |
| #544 | UCB SA | BR:UCB | $49.68 Billion | €274.90 |
| #563 | Argen-X | BR:ARGX | $47.14 Billion | €783.60 |
PTC Therapeutics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, PTC Therapeutics Inc's market cap moved from $2.69 Billion to $ 6.23 Billion, with a yearly change of 9.14%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.23 Billion | -1.08% |
| 2025 | $6.30 Billion | +68.28% |
| 2024 | $3.74 Billion | +63.79% |
| 2023 | $2.29 Billion | -27.80% |
| 2022 | $3.17 Billion | -4.17% |
| 2021 | $3.30 Billion | -34.74% |
| 2020 | $5.06 Billion | +27.07% |
| 2019 | $3.98 Billion | +39.95% |
| 2018 | $2.85 Billion | +105.76% |
| 2017 | $1.38 Billion | +52.89% |
| 2016 | $904.98 Million | -66.33% |
| 2015 | $2.69 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 15th, 2026 the market cap of PTC Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.11 Billion USD |
| MoneyControl | $6.11 Billion USD |
| MarketWatch | $6.11 Billion USD |
| marketcap.company | $6.11 Billion USD |
| Reuters | $6.11 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervo… Read more